Alys Pharmaceuticals receives regulatory approvals for alopaecia areata drug trial

US-based immuno-dermatology company Alys Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) and Health Canada for a Phase IIa trial of ALY-101 for alopecia areata (AA).